An exploratory multimodal pipeline for recurrence prediction in CRC with XELOX therapy
This feasibility study maps combined blood tumor DNA and clinical data for cancer recurrence prediction, but requires larger prospective validation.
This honest feasibility study demonstrates structural potential for combining ctDNA with clinicopathologic ML for CRC recurrence prediction, achieving AUC 0.695 in 86 patients with 17 recurrences. Authors appropriately acknowledge statistical instability due to limited event count, requiring prospective external validation before clinical use.
What the study was
- Study design
- Exploratory retrospective ML study
- Population
- XELOX-treated CRC patients, single center China
- Sample size
- 86
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Scientific Reports
Why it surfaced
Hypothesis-generating ctDNA + ML pipeline for CRC recurrence; small n but methodologically transparent.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.